{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dimethyl fumarate
to a specific field?
Status:
Investigational
Source:
NCT01390714: Phase 1 Interventional Completed Gastroesophageal Reflux Disease
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
E-3710 (Z-215) is a new proton pump inhibitor (PPI). E-3710 irreversibly inhibited H(+),K(+)-ATPase activity in pig gastric vesicles with an acidic internal environment. E-3710 is a long-acting inhibitor of gastric acid secretion and a promising novel therapy for acid-related diseases, such as gastroesophageal reflux disease. E-3710 is metabolized through oxidation, reduction and conjugation. Unchanged E-3710 was excreted in urine at trace levels but was not detected in faces. The major isozyme contributing to the oxidation of Z-215, including the formation of Z-215 sulphone, was CYP3A4. It is useful for treating gastroesophageal reflux disease in all CYP2C19 genotypes. E-3710 is in phase II clinical trial for the treatment of erosive esophagitis and gastro-esophageal reflux.
Status:
Investigational
Source:
NCT01528111: Phase 1/Phase 2 Interventional Completed Primary Open-angle Glaucoma
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
LX-7101 (Lexicon Pharmaceuticals) was advanced to Phase-I clinical trials for treatment open-angle glaucoma or ocular hypertension. This drug is a potent inhibitor of LIM-kinase 2 (LIMK2) kinase and inhibits to less extent LIMK1 and Rho-associated protein kinase 2 (ROCK2).
Status:
Investigational
Source:
NCT01642758: Phase 2 Interventional Completed Beta Thalassemia Intermedia
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
2,2-DIMETHYLBUTYRIC ACID (HQK-1001) is an orally administered SCFAD (Short Chain Fatty Acid Derivative), which has shown an excellent safety profile and biologic effects on fetal hemoglobin induction and red blood cell production in the laboratory, relevant animal models, and in clinical trials carried out in healthy human subjects as well as patients with sickle cell disease and beta thalassemia. The compound has received Orphan Drug Designation in the United States and Europe for both sickle cell disease and beta thalassemia. HemaQuest Pharmaceuticals was developing HQK-1001 for the oral treatment of sickle cell anaemia and beta thalassaemia. HQK-1001 has been evaluated in phase II trials for beta thalassaemia and sickle cell anaemia.
Status:
Investigational
Source:
Redox Rep. 2011;16(3):91-100.: Phase 2 Veterinary clinical trial Completed Mouth Neoplasms/chemically induced/pathology/prevention & control
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01585792: Phase 3 Interventional Completed Diabetic Patients
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
TAK-875 (Fasiglifam) is the potent, selective and orally bioavailable GPR40 agonist. The drug was in Phase III clinical trials for the treatment of type 2 diabetes mellitus. Termination phase III development of TAK-875 for the potential treatment of type-2 diabetes mellitus was announced in 2013 due to concerns about liver safety.
Status:
Investigational
Source:
NCT04450602: Not Applicable Interventional Completed Androgenetic Alopecia
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03765983: Phase 2 Interventional Active, not recruiting Breast Cancer
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01111955: Phase 2 Interventional Completed Diabetes Mellitus, Type 2
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Class (Stereo):
CHEMICAL (RACEMIC)
Trepirium is a ganglion-blocking agent. During clinical testing of the administration of ganglion-blocking agent by inhalation it was established that drug aerosol of trepirium possesses high effectiveness, acts rapidly, and is relatively safe. Trepirium does not cause any local irritating effect. It blocks the n-cholinergic receptors of the autonomic ganglia (it inhibits the transmission of excitation from the preganglionic to the postganglionic fibers of the autonomic nerves) of the adrenal medulla and the sinocarotid region. Reduces the flow of vasoconstrictor impulses to the vessels and adrenaline secretion by the adrenal glands, weakens reflex pressor reactions, and lowers blood pressure. Trepirium is used for the treatment of cerebral or pulmonary edema, hypertensive crisis, nephropathy and eclampsia (in obstetric practice), for the hypotension control in anesthesia practice.
Status:
Investigational
Source:
NCT01581138: Phase 2 Interventional Completed Chronic Hepatitis C Virus
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Lomibuvir (VCH-222) is a novel, potent and selective inhibitor of non-nucleoside polymerase of the hepatitis C virus (HCV) RNA-dependent RNA polymerase, with an IC50 range of 0.94-1.2 μM. Lomibuvir was generated from ViroChem's research programme investigating HCV NS5B polymerase inhibitors. In phase 1 and 2 clinical studies, Lomibuvir demonstrated effective antiviral efficacy, with substantial reductions in plasma HCV RNA in patients chronically infected with genotype 1 HCV. On 15 May 2014 Vertex Pharmaceuticals completes a phase II trial in Hepatitis C (treatment-naive, combination therapy) in USA, Canada, Germany, Poland and United Kingdom (NCT01516918). On 26 Jul 2016 Trek Therapeutics acquires lomibuvir from Vertex Pharmaceuticals.
